13 research outputs found
Recommended from our members
Cytotoxic activity of Indian, Indonesian and UK plant extracts on breast cancer cells
This thesis was submitted for the award of Doctor of Philosophy and was awarded by Brunel University LondonMany plants in biodiversity hotspots have not yet been screened for biological activity in humans. Plants synthesise secondary metabolites that may be unique to each species or induced in response to specific conditions. Assam in North East India forms part of the Indo-Burma biodiversity hotspot for conservation and is a rich source of medicinal plants for traditional Indian medicine. This study concerns the potential cytotoxic effects of three Assamese medicinal plant extracts, from Clitoria ternatea root, Mucuna pruriens seed and Cheilocostus speciosus rhizome. The aim of the study was to characterise the cytotoxic activity, to elucidate the biological mechanism and to isolate the bioactive agents for further investigation. Clitoria was prioritised for study, as its crude extract was found to have a dose related, cytotoxic effect that was 2-3 fold more effective on breast cancer cells than non-cancer cells. Two bioactive fractions of Clitoria were isolated in bioassay-led fractionation with high performance liquid chromatography. The fractions demonstrated a selective dose related cytotoxic effect over a range of 100 to 700 ng/ÎŒL. In live cell observation, crude extract and a bioactive fraction were cytostatic at non-lethal treatment doses, and crude extract reduced cellsâ motility by 50%. Both crude extract and fractions caused structural changes in the actin cytoskeleton which could be contributing to the cytotoxic and cytostatic effects and reduced motility. Liquid Chromatography-Mass Spectrometry analysis indicates that the two isolated bioactive agents are novel homoisoflavones, polyphenolic secondary metabolites, which were also detected in extracts made from Indonesian sourced Clitoria root and are likely to be in extract made from UK sourced Clitoria root. Results suggest that bioactive components of Clitoria extract are worthy of further study and may provide lead compounds for new cytotoxic or antiproliferative anti-cancer therapies.Brunel University Londo
Platelet rich plasma injection for acute Achilles tendon rupture: PATH-2 randomised, placebo controlled, superiority trial
Objective
To determine whether an injection of platelet rich plasma improves outcomes after acute Achilles tendon rupture.
Design
Randomised, placebo controlled, two arm, parallel group, participant and assessor masked, superiority trial.
Setting
Secondary care trauma units across 19 hospitals in the United Kingdomâs health service.
Participants
Recruitment commenced in July 2015 and follow-up was completed in March 2018. 230 adults aged 18 years and over were included, with acute Achilles tendon rupture presenting within 12 days of injury and managed with non-surgical treatment. Exclusions were injury at the insertion or musculotendinous junction, major leg injury or deformity, diabetes mellitus, platelet or haematological disorder, systemic corticosteroids, anticoagulation treatment, and other contraindicating conditions.
Interventions
Participants were randomised 1:1 to platelet rich plasma (n=114) or placebo (dry needle; n=116) injection. All participants received standard rehabilitation care (ankle immobilisation followed by physiotherapy).
Main outcomes and measures
Primary outcome was muscle tendon function at 24 weeks, measured objectively with the limb symmetry index (injured/uninjuredĂ100) in maximal work done during the heel rise endurance test (an instrumented measure of repeated single leg heel rises until fatigue). Secondary outcomes included patient reported function (Achilles tendon rupture score), quality of life (short form 12 version 2Âź), pain (visual analogue scale), goal attainment (patient specific functional scale), and adverse events. A central laboratory analysed the quality and content of platelet rich plasma. Analyses were by modified intention to treat.
Results
Participants were 46 years old on average, and 57 (25%) of 230 were female. At 24 weeks, 202 (88%) participants completed the heel rise endurance test and 216 (94%) the patient reported outcomes. The platelet rich plasma was of good quality, with expected growth factor content. No difference was detected in muscle tendon function between participants receiving platelet rich plasma injections and those receiving placebo injections (limb symmetry index, mean 34.7% (standard deviation 17.7%) v 38.5% (22.8%); adjusted mean difference â3.9% (95% confidence interval â10.5% to 2.7%)) or in any secondary outcomes or adverse event rates. Complier average causal effect analyses gave similar findings.
Conclusions
There is no evidence to indicate that injections of platelet rich plasma can improve objective muscle tendon function, patient reported function, or quality of life after acute Achilles tendon rupture compared with placebo, or that they offer any patient benefit.
Trial registration
isrctn.com identifier: ISRCTN54992179</p
Platelet-rich plasma in Achilles tendon healing 2 (PATH-2) trial: statistical analysis plan for a multicentre, double-blinded, parallel-group, placebo-controlled randomised clinical trial.
BACKGROUND: There has been a recent steep growth in platelet-rich plasma (PRP) use for musculoskeletal conditions, but findings from high quality clinical trial data are lacking in the literature. Here, we describe the statistical analysis plan (SAP) for the Platelet-rich plasma in Achilles Tendon Healing 2 (PATH-2) trial. METHODS: PATH-2 is a pragmatic, parallel-group, multi-centre, double-blinded, randomised, placebo-controlled, superiority trial. The study aims to evaluate the clinical efficacy of PRP in acute Achilles tendon rupture in terms of muscle-tendon function. Patients are identified in the orthopaedic/trauma outpatient clinic. The primary outcome is muscle-tendon work capacity from the Heel Rise Endurance Test result, expressed as the Limb Symmetry Index (work, in joules), at 24Â weeks post randomisation. Multivariate linear regression adjusting for the stratification factors (centre and age) and additional prognostic factors will be used to investigate the adjusted effect of the intervention. The analysis will be by modified intention-to-treat. Sensitivity analysis will assess the internal validity of the trial results by performing a per-protocol analysis. Safety will be summarised by treatment arm for all patients who started treatment. Secondary patient-reported outcome measures will be analysed using linear mixed effects models to allow all data collected at all follow-up points to be considered. Missing data will be summarised and reported by treatment arm. Missing data imputation will be performed, if appropriate. DISCUSSION: The PATH-2 trial will be reported in accordance with the CONSORT statement. This SAP publication will avoid bias arising from prior knowledge of the study results. Any changes or deviations from the current SAP will be described and justified in the final report. TRIAL REGISTRATION: ISRCTN registry: ISRCTN54992179 , assigned 12 January 2015. ClinicalTrials.gov: NCT02302664, received 18 November 2014. UK Clinical Research Network Study Portfolio Database: ID 17850
Platelet rich plasma injection for acute Achilles tendon rupture: PATH-2 randomised, placebo controlled, superiority trial
Platelet Rich Plasma injection versus placebo injection in adults with acute Achilles tendon ruptures:the PATH-2 multicentre randomised controlled trial
Platelet rich plasma injection for acute Achilles tendon rupture: two-year follow-up of the PATH-2 randomised, placebo-controlled, superiority trial
Aims: To determine whether platelet-rich plasma (PRP) injection improves outcomes two years after acute Achilles tendon rupture.
Methods: A randomized multicentre two-arm parallel-group, participant- and assessor-blinded superiority trial was undertaken. Recruitment commenced on 28 July 2015 and two-year follow-up was completed in 21 October 2019. Participants were 230 adults aged 18 years and over, with acute Achilles tendon rupture managed with non-surgical treatment from 19 UK hospitals. Exclusions were insertion or musculotendinous junction injuries, major leg injury or deformity, diabetes, platelet or haematological disorder, medication with systemic corticosteroids, anticoagulation therapy treatment, and other contraindicating conditions. Participants were randomized via a central online system 1:1 to PRP or placebo injection. The main outcome measure was Achilles Tendon Rupture Score (ATRS) at two years via postal questionnaire. Other outcomes were pain, recovery goal attainment, and quality of life. Analysis was by intention-to-treat.
Results: A total of 230 participants were randomized, 114 to PRP and 116 to placebo. Two-year questionnaires were sent to 216 participants who completed a six-month questionnaire. Overall, 182/216 participants (84%) completed the two-year questionnaire. Participants were aged a mean of 46 years (SD 13.0) and 25% were female (57/230). The majority of participants received the allocated intervention (219/229, 96%). Mean ATRS scores at two years were 82.2 (SD 18.3) in the PRP group (n = 85) and 83.8 (SD 16.0) in the placebo group (n = 92). There was no evidence of a difference in the ATRS at two years (adjusted mean difference -0.752, 95% confidence interval -5.523 to 4.020; p = 0.757) or in other secondary outcomes, and there were no re-ruptures between 24 weeks and two years.
Conclusion: PRP injection did not improve patient-reported function or quality of life two years after acute Achilles tendon rupture compared with placebo. The evidence from this study indicates that PRP offers no patient benefit in the longer term for patients with acute Achilles tendon rupture
The ENABLE study protocol: Understanding and characterising the value and role of selfâmanagement support for people living with cancer that is treatable but not curable
ObjectiveAttention is turning to the needs of people living with treatable but incurable cancer, a group with complex needs, living with uncertainty over time. More research is needed to understand how this group selfâmanage the impact of cancer to strengthen the evidence base for interventions. This study aims to understand the value and outcomes of selfâmanagement support for people living with treatable but incurable cancer.MethodsQualitative longitudinal methods will examine how support needs change over time in relation to selfâmanagement and unpredictable disease trajectories. Thirty patients and 30 carers will be recruited from two hospitals, each participating in three interviews over 1 year. Patients will be purposively sampled according to age, gender, cancer type and anticipated survival. Carers will be recruited via nomination by patients but interviewed separately. Oneâoff interviews will be conducted with 20 healthcare professionals, providing data from multiple perspectives. Based on interview findings, a modified Delphi process will map areas of consensus and disparity regarding conceptualisations and outcomes of selfâmanagement support.ConclusionThe key output will be practice recommendations in relation to selfâmanagement support, producing evidence to inform service innovation for those living with treatable but incurable cancer
Platelet rich plasma injection for acute Achilles tendon rupture: two-year follow-up of the PATH-2 randomised, placebo-controlled, superiority trial
Aims: To determine whether platelet-rich plasma (PRP) injection improves outcomes two years after acute Achilles tendon rupture.
Methods: A randomized multicentre two-arm parallel-group, participant- and assessor-blinded superiority trial was undertaken. Recruitment commenced on 28 July 2015 and two-year follow-up was completed in 21 October 2019. Participants were 230 adults aged 18 years and over, with acute Achilles tendon rupture managed with non-surgical treatment from 19 UK hospitals. Exclusions were insertion or musculotendinous junction injuries, major leg injury or deformity, diabetes, platelet or haematological disorder, medication with systemic corticosteroids, anticoagulation therapy treatment, and other contraindicating conditions. Participants were randomized via a central online system 1:1 to PRP or placebo injection. The main outcome measure was Achilles Tendon Rupture Score (ATRS) at two years via postal questionnaire. Other outcomes were pain, recovery goal attainment, and quality of life. Analysis was by intention-to-treat.
Results: A total of 230 participants were randomized, 114 to PRP and 116 to placebo. Two-year questionnaires were sent to 216 participants who completed a six-month questionnaire. Overall, 182/216 participants (84%) completed the two-year questionnaire. Participants were aged a mean of 46 years (SD 13.0) and 25% were female (57/230). The majority of participants received the allocated intervention (219/229, 96%). Mean ATRS scores at two years were 82.2 (SD 18.3) in the PRP group (n = 85) and 83.8 (SD 16.0) in the placebo group (n = 92). There was no evidence of a difference in the ATRS at two years (adjusted mean difference -0.752, 95% confidence interval -5.523 to 4.020; p = 0.757) or in other secondary outcomes, and there were no re-ruptures between 24 weeks and two years.
Conclusion: PRP injection did not improve patient-reported function or quality of life two years after acute Achilles tendon rupture compared with placebo. The evidence from this study indicates that PRP offers no patient benefit in the longer term for patients with acute Achilles tendon rupture
Platelet Rich Plasma injection versus placebo injection in adults with acute Achilles tendon ruptures:the PATH-2 multicentre randomised controlled trial
âIt feels itâs wasting whatever time Iâve got leftâ: A qualitative study of living with treatable but not curable cancer during the COVID-19 pandemic
Background: People living with cancer that is treatable but not curable have complex needs, often managing health at home, supported by those close to them. Challenges are likely to be exacerbated during the COVID-19 pandemic and the risk-reducing measures introduced in response. The impact of COVID-19 on those living with incurable, life-threatening conditions is little understood. Aim: To investigate the experiences and identify the impact of the COVID-19 pandemic for people living with treatable not curable cancer and their informal carers. Design: Qualitative semi-structured phone interviews were conducted with 21 patients living with cancer that is treatable but not curable and 14 carers. Setting/ participants: Participants were part of a larger longitudinal qualitative study (ENABLE) on supported self-management for people living with cancer that is treatable but not curable. Results: The COVID-19 pandemic magnified uncertainty and anxiety and led to loss of opportunities to do things important to patients in the limited time they have left to live. Lack of face-to-face contact with loved ones had a significant impact on patientsâ and carersâ emotional wellbeing. Carers experienced increased responsibilities but less access to formal and informal support and respite. While changes to treatment led to some concern about longer-term impact on health, most patients felt well-supported by healthcare teams. Conclusion: The study provides rich insights into the nature of challenges, uncertainty and lost opportunities resulting from the COVID-19 pandemic for patients and carers living with cancer that is treatable but not curable, which has wider resonance for people living with other life-limiting conditions.</p